Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-10
DOI
10.1038/s41467-021-27833-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PI3K inhibitors are finally coming of age
- (2021) Bart Vanhaesebroeck et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Functional genomic landscape of cancer-intrinsic evasion of killing by T cells
- (2020) Keith A. Lawson et al. NATURE
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity
- (2019) Shiying Wu et al. NATURE CELL BIOLOGY
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
- (2019) H. Taghizadeh et al. OncoImmunology
- Defining body-weight reduction as a humane endpoint: a critical appraisal
- (2019) Steven R Talbot et al. LABORATORY ANIMALS
- Co-Targeting the Cell Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ inhibitor BAY1082439
- (2018) Yongkang Zou et al. MOLECULAR CANCER THERAPEUTICS
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
- (2018) Arianna Calcinotto et al. NATURE
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
- (2018) Caroline S. Jansen et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
- (2018) Peng Yue et al. OncoImmunology
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
- (2016) E. Toska et al. CLINICAL CANCER RESEARCH
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Landscape of tumor-infiltrating T cell repertoire of human cancers
- (2016) Bo Li et al. NATURE GENETICS
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
- (2016) Marco A. De Velasco et al. Oncotarget
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
- (2014) Bart Vanhaesebroeck et al. CANCER CELL
- Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
- (2014) A. J. Garcia et al. MOLECULAR AND CELLULAR BIOLOGY
- Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
- (2014) Diletta Di Mitri et al. NATURE
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee
- (2013) M. Ittmann et al. CANCER RESEARCH
- Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
- (2012) S. Tang et al. CANCER RESEARCH
- Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
- (2012) D. J. Mulholland et al. CANCER RESEARCH
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
- (2012) Cole Trapnell et al. Nature Protocols
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
- Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
- (2011) David J. Mulholland et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
- (2010) Massimo Ammirante et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started